Wound care company Spectral MD targets London IPO

The technology already has 'breakthrough device' designation status from the US FDA for burns but is targeting a larger market

medical AI

A company that has developed a technology that uses artificial intelligence to help make faster decisions in wound care is planning to float on AIM to raise funds to undertake more clinical trials and open a UK base.

Spectral MD Holdings Ltd's DeepView wound imaging solution is an internally developed AI and multispectral imaging technology that enables the user to distinguish between damaged and healthy human tissue, invisible to the naked eye, providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers (DFU).

It already has 'breakthrough device' designation status from the US Food & Drug Administration (FDA), for the burn indication.

But Texas-headquartered Spectral MD is targeting the larger commercial market of the DFU application and that is why it is seeking a placing of shares with UK investors for funds to undertake additional clinical trials for the DFU in the US, UK and EU.

The company said is also looking to develop a UK-based EMEA headquarters to support CE-Mark approval and commercial expansion.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Altus Strategies' 'transformational transaction', the $34mln deal with...

Mining Capital's Alastair Ford joins Proactive London to discuss Altus Strategies PLC (AIM:ALS, TSX-V:ALTS, OTCQX:ALTUF) (AIM:ALS, TSX-V:ALTS, OTCQX:ALTUF).  The company has just completed on what Ford describes as a 'transformational transaction', the US$34mln acquisition of the Caserones...

39 minutes ago

2 min read